BioCentury | Jun 16, 2020
Product Development

Bit Bio scales up cell programming ambitions with $41.5M from blue-chip investors

...cell type in the human body within 10 years. Formerly known as Elpis Biomed Ltd., Bit Bio Ltd.’s...
...Bio will share its biological findings, while retaining rights to commercial applications. Karen Tkach Tuzman, Associate Editor bit bio Ltd. Mark...
BioCentury | Jun 8, 2018
Company News

Luye, Elpis collaborate on dual-targeting CAR Ts

...Luye Pharma Group Ltd. (HKSE:2186) and Elpis Biopharmaceuticals Corp. (Mass.) partnered to discover and develop dual-targeting...
...partnered to discover and develop dual-targeting CAR T therapies. Luye declined to disclose specific targets. Elpis...
...to develop immuno-oncology therapies, under which they have a CAR T therapy in IND-enabling studies. Elpis...
BioCentury | May 25, 2017
Emerging Company Profile

Total reprogramming

...University of Cambridge spinout Elpis Biomed Ltd. has a platform that rapidly produces stockpiles of pure...
...can require months of culture, making it challenging to scale their production for commercial use. Elpis'...
...Elpis’ platform. “On a monthly basis, there's another set of transcription factors available," he said. Elpis...
BioCentury | Apr 18, 2017
Distillery Techniques

Disease models

...fibroblast growth factor 2 (FGF2) generated cells expressing markers of mature oligodendrocytes. Next steps by Elpis...
...cell types for use in cell-based disease models LICENSING STATUS: Patent application filed; licensed to Elpis...
...Cambridge, Cambridge, U.K. email: pawlowsk@uni-muenster.de CONTACT: Mark R.N. Kotter, same affiliation as above email: mrk25@cam.ac.uk Hongjiang Li Elpis...
Items per page:
1 - 4 of 4
BioCentury | Jun 16, 2020
Product Development

Bit Bio scales up cell programming ambitions with $41.5M from blue-chip investors

...cell type in the human body within 10 years. Formerly known as Elpis Biomed Ltd., Bit Bio Ltd.’s...
...Bio will share its biological findings, while retaining rights to commercial applications. Karen Tkach Tuzman, Associate Editor bit bio Ltd. Mark...
BioCentury | Jun 8, 2018
Company News

Luye, Elpis collaborate on dual-targeting CAR Ts

...Luye Pharma Group Ltd. (HKSE:2186) and Elpis Biopharmaceuticals Corp. (Mass.) partnered to discover and develop dual-targeting...
...partnered to discover and develop dual-targeting CAR T therapies. Luye declined to disclose specific targets. Elpis...
...to develop immuno-oncology therapies, under which they have a CAR T therapy in IND-enabling studies. Elpis...
BioCentury | May 25, 2017
Emerging Company Profile

Total reprogramming

...University of Cambridge spinout Elpis Biomed Ltd. has a platform that rapidly produces stockpiles of pure...
...can require months of culture, making it challenging to scale their production for commercial use. Elpis'...
...Elpis’ platform. “On a monthly basis, there's another set of transcription factors available," he said. Elpis...
BioCentury | Apr 18, 2017
Distillery Techniques

Disease models

...fibroblast growth factor 2 (FGF2) generated cells expressing markers of mature oligodendrocytes. Next steps by Elpis...
...cell types for use in cell-based disease models LICENSING STATUS: Patent application filed; licensed to Elpis...
...Cambridge, Cambridge, U.K. email: pawlowsk@uni-muenster.de CONTACT: Mark R.N. Kotter, same affiliation as above email: mrk25@cam.ac.uk Hongjiang Li Elpis...
Items per page:
1 - 4 of 4